Truvian key facts
- Developer of an automated blood testing and diagnostic technology designed to deliver a convenient and affordable alternative to off-site labs.
- Truvian’s last known valuation is $329.0M.
- It has raised $294.4M; the latest was Later Stage VC ($74.0M) in Jul 2024.
- Notable investors include General Catalyst, CONNECT(San Diego), GreatPoint Ventures, DNS Capital, Tao Capital Partners — 19 tracked in total.
- Status: Privately Held (backing).
Who backs Truvian
19+- ·The complete investor list: 19 names
- ·Watch Truvian: the Monday email on marks, rounds and moves
Truvian funding rounds
No funding rounds for Truvian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Truvian valuation
Truvian's last known valuation is $329 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Truvian investors
19 investors are on record for Truvian, including General Catalyst, CONNECT(San Diego), GreatPoint Ventures and DNS Capital. By type, the record holds 6 venture capital firms and 3 family offices.
About Truvian
Developer of an automated blood testing and diagnostic technology designed to deliver a convenient and affordable alternative to off-site labs. The company's technology combines clinical chemistries, immunoassays, and hematology assays all within one instrument, in a single run and provides lab-accurate results in less time for a suite of health tests, enabling healthcare professionals to get access to comprehensive, easy-to-understand lab test reports and insights while also making routine health testing suitable and reasonable.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2015
- Employees
- 119
- Website
- truvianhealth.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Truvian’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.